Benzinga | Nov 15, 2021 10:46AM EST

SVB Leerink Maintains Outperform on Ascendis Pharma, Raises Price Target to $190

SVB Leerink analyst Joseph Schwartz maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $182 to $190.